Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BD and Biodiversity collaborate on infection tests for transplant patients

This article was originally published in Clinica

Executive Summary

Privately-held Italian biotech firm Biodiversity is teaming up with BD Diagnostics to develop and commercialise a menu of molecular diagnostics for immunocompromised patients which will run on the BD Max system. Biodiversity will develop the tests, which will be designed to improve the monitoring of infections in transplant recipients who are at high risk because of the immunosuppressant drugs needed to prevent transplant rejection. The assays produced through the collaboration are intended to be CE marked for sale in Europe initially – this could later be expanded to include approval in other countries and regions, according to the companies. BD Diagnostics, part of Becton Dickinson, is currently expanding the menu for its automated BD Max system, and there are currently 15 tests in the pipeline. Earlier this month, the company agreed to develop a BD Max test for Aspergillus infection with personalised medicine specialist Lab21.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT097766

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel